Chronic HBV infection affects around 350 million people worldwide [1] . Carriers can develop liver failure or hepatocellular carcinoma [2] . Despite the availability of an effective HBV vaccine since 1983, new HBV infections continue to occur in relatively high numbers worldwide [3] . Lamivudine (3TC) was approved as the first anti-HBV oral agent in 1998; however, the widespread use of 3TC as a single oral antiviral agent until recently has led to the selection of resistance in a substantial proportion of treated patients (23% at 1 year and 80% after 5 years of monotherapy) [4] . This drawback has multiple consequences beyond the lack of further clinical benefit of 3TC monotherapy in a given patient. Cross-resistance to other antiviral agents, such as telbivudine and to a lesser extent entecavir [4] , and selection of antiviral drug associated potential vaccine-escape mutants [5, 6] are major concerns associated with the selection of 3TC resistance associated mutations in HBV.
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Transmission of a 3TC-resistant HBV strain (rtL180M+rtM204V) was originally reported in [7] . The patient developed acute hepatitis and subsequently cleared the infection spontaneously. Interestingly, the level of HBV viraemia was lower than that usually observed during the acute phase of HBV infection, suggesting a potential impaired viral fitness for the 3TC-resistant HBV strain. Since then, several studies have reported rates of around 8% for primary drug resistance mutations in drug-naive HBV-monoinfected individuals in Western countries [8, 9] and China [10] . Of note, these patients are prone to experience subsequent failure on antiviral therapy [9] . In most cases, 3TC resistance mutations are the ones recognized.
As 3TC has been widely used as part of antiretroviral regimens for the past 15 years, often as single anti-HBV agent, the selection of 3TC-resistant HBV variants in HIV-HBV-coinfected patients would be expected to occur frequently [11] , although this might go unnoticed. Given that risk practices, including a high number of sexual partners, are more frequent in HIV-infected persons than in the general population, transmission of 3TC-resistant HBV strains within the HIV community would be expected to be higher. Herein, we report the results of a large survey examining HBV resistance in newly diagnosed antiretroviral-naive HIV-HBV-coinfected individuals in Spain.
Methods

Study population
All individuals that were positive for serum hepatitis B surface antigen (HBsAg) were identified within the Cohorte de la Red de Investigación en SIDA (CoRIS), which is linked to a Biobank. CoRIS is a prospective cohort of antiretroviral-naive patients aged over 13 years seen for the first time since January 2004 onwards in any of 19 hospitals distributed across the Spanish geography. For this analysis, administrative censoring took place in December 2008. Other relevant features of this cohort have been described elsewhere [12] .
Samples from patients were kindly provided by the HIV BioBank, which is part of the Spanish AIDS Research Network (RIS) [13] . Blood samples were processed following standard procedures and frozen immediately after their collection. All patients participating in the study gave informed consent and protocols were approved by institutional ethics committees.
HBV viral markers
HBV DNA extraction was carried out on stored sera using the Qiagen DNA blood kit (Qiagen, Mannheim, Germany) following manufacturer's instructions. Serum HBV DNA was measured using a commercial real-time PCR method (Roche, Barcelona, Spain), which has a lower limit of detection of 10 IU/ml. The reverse transcriptase (RT) from each HBV isolate was amplified using a nested PCR protocol, as previously described [14] , and then sequenced and analysed for drug resistance mutations using a commercial assay (Trugene, Siemens, Barcelona, Spain).
The HBV vaccine-escape and RT drug resistance mutations selected by antiviral agents were examined using a bioinformatic algorithm known as geno2pheno[hbv] [15] .
Statistical analysis
The main baseline characteristics of the study population are recorded as absolute numbers and percentages. Comparisons between groups were performed using the Student's t-test when assessing means and the χ 2 test when comparing proportions. For all analyses, the level of significance was set at P-values <0.05. All statistical analyses were performed using the SPSS statistical package version 15.0 software (SPSS Inc, Chicago, IL, USA).
Results
Until December 2008, the CoRIS cohort had enrolled 4,419 newly diagnosed HIV-1-infected individuals. Of these, 223 (5.1%) were positive for serum HBsAg, 3,601 (81.5%) were HBsAg-negative and 595 (13.5%) had an unknown HBsAg status. For the subset of serum HBsAg-positive patients, 84 (37.7%) had stored baseline frozen specimens; however, serum HBV DNA was undetectable or too low to allow further HBV virological characterization in 11 of them. Table 1 summarizes the main characteristics of the whole serum HBsAgpositive population and the subset of 73 individuals in whom virological studies could subsequently be performed. Overall, there were no statistically significant differences when comparing distinct variables in these two populations.
The HBV genotype distribution was as follows: 45 A (19 A1 and 26 A2), 14 F (10 F1 and 4 F2), 10 D (2 D1, 5 D2 and 3 D3), 1 E, 2 G and 1 H. Four patients (5.5%) showed drug resistance associated mutations in the HBV polymerase: the rtL180M mutation was identified in two, rtL80V in one and rtV173L in one. None showed M204V, the primary 3TC resistance change in HBV. Interestingly, none of these four individuals displayed mutations associated with drug resistance in the HIV genome. All were men who had sex with men (MSM), infected with HBV subtype A2 and native Spaniards. Table 2 summarizes the main characteristics of these individuals.
A total of seven patients harboured changes at the S gene: sT128V (n=1), sT128V+sN144A (n=1), sL109I+sP120Q (n=1), sF134S+sG145K (n=1) and sG100C (n=3). According to geno2pheno [hbv] , none of these changes represented a potential HBV vaccineescape mutant.
Discussion
Primary HBV resistance to oral antiviral agents reflects in almost all cases transmission of a drug-resistant HBV strain from individuals who had been exposed to and virologically failed to prior antiviral therapy, mainly 3TC monotherapy [8] [9] [10] 16 ]. In only rare instances, such as the L217R change in HBV subtype A2 which could compromise the response to adefovir [17, 18] , natural polymorphisms causing diminished susceptibility to anti-HBV agents might be involved. This observation has been confirmed by studies conducted before the widespread use of 3TC as oral HBV therapy. For example, samples from 160 acute hepatitis B patients collected a decade ago in England did not show any single case of primary HBV drug resistance, despite the fact that most patients were intravenous drug users or MSM [19] , as in our study.
The four individuals harbouring 3TC-resistant HBV mutants in our study were MSM and native Spaniards. Not surprisingly, all were infected with HBV subtype A2, which is the most frequently circulating variant in the European HIV population [20] . Interestingly, the major 3TC resistance mutation was absent in all cases; instead compensatory or secondary changes (rtL80V, rtV173L or rtL180M) were found in 5.5% of patients. This observation is somewhat unexpected and is in contrast with others studies, which have found rtM204V alone or in combination with some compensatory changes, in similar cases of transmission of 3TC-resistant HBV strains in HIV patients [7, 21] or in cross-sectional studies in HIV-HBV-coinfected patients receiving 3TC-containing regimens [22] . The use of population genetic sequencing for screening HBV drug resistance mutations in our study might have missed viral variants present at low levels. In this regard, the performance of clonal analysis or ultradeep sequencing might have allowed the identification of more HBV genomes harbouring drug resistance mutations, present as minority populations owing to impaired viral fitness [23] . Studies are ongoing to address this issue. Although potential HBV vaccine-escape mutants were not identified in our study population, the risk for transmission of such HBV variants has recently been highlighted [6, 16] . Given the fact that the HBV polymerase gene overlaps the viral envelope gene, resistance changes induced by antiviral drugs in the polymerase might modify the HBsAg antigenicity, potentially allowing evasion from neutralizing antibodies raised against HBsAg, such as those elicited by the HBV vaccine. In this way, infection of HBV vaccinated individuals by these HBV mutants could hypothetically occur.
In summary, our results support the idea that the selection of 3TC-resistant HBV strains poses a significant threat for the community, besides its deleterious effect for the individual who fails therapy. The recognition of primary 3TC-resistant HBV strains suggests that transmission of these variants is already occurring. Although still at low frequency, periodic surveys must be conducted as increasing rates of transmission of drug-resistant HBV strains might justify adoption of drug resistance testing before prescription of oral antiviral therapy, as currently takes place in the management of HIV infection [24] . Moreover, as some of these drug-resistant HBV variants might behave as vaccine-escape mutants, infection of vaccinated individuals by these viruses warrants close monitoring. In the mean time, the lesson to be learnt from the HIV-HBV-coinfected population is that, whenever possible, 3TC must be avoided as single anti-HBV agent in antiretroviral regimens. The immediate benefit seems too risky in the long-term [25] , as the experience in South Africa has recently shown [26] . The use of tenofovir alone or, better still, in combination with either 3TC or emtricitabine should be considered as the preferred option for treating HIV-HBV-coinfected patients [27] .
